RecruitingNCT04655235

Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia

Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia - a Combined EEG-, FMRI-, Genetic, Serological and Cell Biological Study


Sponsor

RWTH Aachen University

Enrollment

600 participants

Start Date

Oct 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

In the last years, the imbalance between excitatory and inhibitory neuronal activity has come to the fore as a possible molecular disease mechanism of schizophrenia . Pharmacological studies have suggested different fMRI and EEG markers of that molecular dysfunction (resting state connectivity changes, auditory mismatch and steady state deficits). However, previous research is inconclusive regarding their genetic basis, their reliability, inter-individual relationship as well as disease specificity. Therefore, in this study we aim at estimating the effect sizes, test-retest-reliability and clinical correlates of the respective markers in a comparative fashion in patients with schizophrenia, their relatives and healthy control subject. To assess their molecular validity, we will assess their relationship with glutamatergic and GABAergic genotypes and cellular disease models. The proof of such a relation would give the opportunity of detecting a glutamatergic and GABAergic imbalance throughout non-invasive imaging. Furthermore, it would help deepening our understanding of the molecular pathophysiology of mental disorders which will be essential for the development of more effective drugs.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study investigates the brain chemistry of people with schizophrenia by examining the glutamate and GABA systems — two key chemical messengers involved in brain signaling. It also recruits healthy volunteers for comparison. No experimental treatment is given. **You may be eligible if...** - You are 18–80 years old - For patients: you have a confirmed diagnosis of schizophrenia (DSM-5) and are mentally capable of giving consent - For healthy volunteers: you are in good mental health with no personal or close family history of psychiatric conditions **You may NOT be eligible if...** - You are pregnant - You have a structural neurological disease (like a brain tumor or past stroke) - For patients: you have another psychiatric condition that is the main clinical concern - For healthy volunteers: you have any psychiatric disorder or a first-degree relative with a psychiatric disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICGenotyping

Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes


Locations(3)

Alexianer Hospital

Aachen, Northrine-Westphalia, Germany

ViaNobis - Die Fachklinik

Gangelt, Northrine-Westphalia, Germany

University hospital RWTH Aachen

Aachen, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04655235


Related Trials